Effect of AGPAT3 overexpression on mTORC1 signaling pathway. by Hadi Alizadeh (20854757)

Subjects:

Differentially expressed genes in A2780 resistant and sensitive to cisplatin ovarian cancer originated cell lines. by Hadi Alizadeh (20854757)

Subjects:

Cell cycle analysis of A2780 cells following AGPAT3 overexpression. by Hadi Alizadeh (20854757)

Subjects:

Characterization of cisplatin resistance phenotype in A2780 and A2780cp cells. by Hadi Alizadeh (20854757)

Subjects:

Viability and drug resistance of A2780 cells following AGPAT3 overexpression. by Hadi Alizadeh (20854757)

Subjects:

Presenting the original images of Western blotting analysis. by Hadi Alizadeh (20854757)

Subjects:

Outcome of AEFIs. by Amma Frempomaa Asare (19751343)

“…The most common AEFIs recorded were headache (52.9%), pains (44.4%), pyrexia (35.1%), chills (16.7%) and injection site pain (15.6%). Relative to those 50 years and above, the odds of serious AEFI were 60% less among those aged <30 years (aOR = 0.40, CI: [0.19, 0.86], p = 0.019). …”

Types of AEFIs reported by vaccine type in Ghana. by Amma Frempomaa Asare (19751343)

“…The most common AEFIs recorded were headache (52.9%), pains (44.4%), pyrexia (35.1%), chills (16.7%) and injection site pain (15.6%). Relative to those 50 years and above, the odds of serious AEFI were 60% less among those aged <30 years (aOR = 0.40, CI: [0.19, 0.86], p = 0.019). …”

Types of AEFIs reported. by Amma Frempomaa Asare (19751343)

“…The most common AEFIs recorded were headache (52.9%), pains (44.4%), pyrexia (35.1%), chills (16.7%) and injection site pain (15.6%). Relative to those 50 years and above, the odds of serious AEFI were 60% less among those aged <30 years (aOR = 0.40, CI: [0.19, 0.86], p = 0.019). …”

Fig 2 - by Masaru Sakai (1669627)

¹³⁷Cs activity concentrations in <i>Aralia elata</i> buds collected in Iitate village, Fukushima from 2014 to 2022. by Masaru Sakai (1669627)

Fig 3 - by Masaru Sakai (1669627)

Data Sheet 1_Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis.pdf by Yan Liu (25061)

“…In vitro, experiments showed that semaglutide decreased the expression of S100A9 by activating the Protein Kinase C(PKC) pathway, thus inhibiting ferroptosis in cardiomyocytes.…”

Data Sheet 2_Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis.docx by Yan Liu (25061)

“…In vitro, experiments showed that semaglutide decreased the expression of S100A9 by activating the Protein Kinase C(PKC) pathway, thus inhibiting ferroptosis in cardiomyocytes.…”

Table 1_Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis.docx by Yan Liu (25061)

“…In vitro, experiments showed that semaglutide decreased the expression of S100A9 by activating the Protein Kinase C(PKC) pathway, thus inhibiting ferroptosis in cardiomyocytes.…”

OPG147 has no effect on TBK1 or IRF3-mediated ISRE activation and HT-DNA-induced signaling. by Xue-Mei Yi (18851202)

Potential signatures of adaptive introgression at <i>SLC30A9</i>. by Ana Roca-Umbert (17041620)

“…The red dot denoted the <i>SLC30A9</i> region. (D) Joint distribution of the U (10%, 50%, 100%) and Q95 (10%, 100%) statistics in CEU and CHB when using either YRI or ESN as unadmixed group. …”

Identification of OPG147 as a conserved inhibitor of the cGAS-mediated pathway. by Xue-Mei Yi (18851202)

Oxytocin decreases postsynaptic CeA spontaneous GABAergic transmission and blocks presynaptic alcohol effects. by Brendan J. Tunstall (6593357)

“…(A, Bottom) Oxytocin decreased sIPSC amplitude from baseline in CeA neurons from both nondependent and dependent rats and caused a small increase from baseline in sIPSC rise time in nondependent rats. …”

Decreases in muscle size, muscle force, and TB mass in 3-mo Lmna^HSA-cko mice. by Lei Xiong (334812)